Default company panoramic image

Laurent Pharmaceuticals

Private company developing a Phase 2a ready, orally-active drug candidate with potential to modulate the immuno-inflammatory response in cystic fibrosis.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Montreal, QC, Canada
  • Currency USD
  • Founded November 2012
  • Employees 1
  • Website

Company Summary

Laurent Pharmaceuticals is dedicated to drug development for orphan diseases, and has a clinical stage lead program in Cystic Fibrosis focusing on Fenretinide, a repurposed but never commercialized oral small molecule drug. Fenretinide was shown to normalize a key fatty acid imbalance, a primary and multi-organ effect in CF, thus having the potential to become a disease-modifying oral drug in a market dominated by palliative inhalation therapies.


  • Default avatar
    Danuta Radzioch
    Chief Scientific Officer

    Dr. Danuta Radzioch, PhD in molecular biology, microbiology and immunology, is a professor in the Faculty of Medicine at McGill University and researcher at RIMUHC. Dr. Radzioch is the originator of the technology involving Fenretinide, and she is an expert in inflammation associated with chronic respiratory diseases, the mechanism of macrophage activation for bactericidal activity, and genetic factors regulating emphysema and asthma.

  • Default avatar
    Radu Pislariu
    President and CEO

    Radu Pislariu, M.D., is an experienced healthcare entrepreneur and investor, with extensive medical and drug development expertise. Previously with iNovia Capital and MSBi Valorisation, Dr. Pislariu was involved in creating and structuring several university spin-offs, as well as leveraging pre-seed, seed and early stage financing rounds, which collectively raised more than $62 million from private and public sources.

  • 25c82b84 9b8d 4253 8e02 1ca9d8f731a8
    Chief Development Officer

    Patrick Colin, B.Pharm., Ph.D., is a seasoned pharmaceutical industry executive who managed drug development programs leading to 15 market approvals in various therapeutic areas. Dr. Colin is the former VP R&D of Axcan Pharma (now Actavis), and more recently, he co-funded GIcare Pharma, a clinical stage gastroenterology company. His credentials include 27 years of global drug development experience in the US, EU and Canada.


  • Default avatar
    Default avatar
    Nadine Boucher

Previous Investors

  • Default avatar
    MSBi Valorisation